Reinfusion of CAR T Therapy Shows Promise in B-ALL
Long term survival was limited and all patients with B-cell acute lymphoblastic leukemia eventually relapsed.
Exploring NG-641 Plus Nivolumab for Previously Treated Metastatic or Advanced Epithelial Tumors
Already, NG-641 has shown encouraging preliminary safety and tolerability results in the ongoing phase 1a dose-escalation STAR trial (NCT04053283), which is a first-in-human study for the gene therapy.
In B-Cell NHL, Off-the-Shelf NK Immunotherapy Shows Promise When Used With Chemotherapy and ASCT
Findings presented at the 2021 Transplant & Cellular Therapy Meetings indicate that patients with B-cell non-Hodgkin lymphoma may benefit from a type of natural killer immunotherapy added to chemotherapy and transplant.
Cilta-Cel Induces High Response Rate in Relapsed/Refractory Multiple Myeloma
Treatment with the CAR T-cell therapy ciltacabtagene autoleucel led to a high response rate and an acceptable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.
Cilta-Cel Confers 97% ORR in Relapsed/Refractory Multiple Myeloma
December 5, 2020 - Treatment with the CAR T-cell therapy ciltacabtagene autoleucel led to a high response rate and an acceptable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.
FDA Grants Fast Track Designation to AMG 510 for KRAS G12C+ NSCLC
The FDA has granted a fast track designation to AMG 510 for the treatment of patients with KRAS G12C–mutated metastatic non–small cell lung cancer who received prior therapy.
Lisocabtagene Maraleucel Shows Promising Response Rates in Relapsed/Refractory MCL
The CAR T-cell therapy lisocabtagene maraleucel elicited a 71% overall response rate as well as a tolerable safety profile in a cohort of patients with relapsed/refractory mantle cell lymphoma.
FDA Grants P-BCMA-101 CAR T-Cell Therapy Orphan Drug Designation for Myeloma
The FDA has granted an orphan drug designation to the autologous CAR T-cell therapy P-BCMA-101 for the treatment of patients with relapsed/refractory multiple myeloma.
2 Clarke Drive Cranbury, NJ 08512